Prescribing Disulfiram

Why Disulfiram Still Matters

Disulfiram is the oddball of the addiction pharmacopeia. Naltrexone, acamprosate, topiramate: every other medication used for alcohol use disorder (AUD) works by turning down the wanting, blunting the reward, quieting the craving, rebalancing glutamate. Disulfiram does none of that. It leaves the craving fully intact and instead installs a hard, chemical consequence for drinking. Take it, drink alcohol, and within minutes the patient is flushed, nauseated, pounding, and miserable. The drug doesn't make the patient not want to drink. It makes drinking cost something immediate and physical.

That mechanism is exactly why disulfiram fell out of favor, and exactly why it deserves a place in your toolkit. It fell out of favor because it fails the randomized-controlled-trial test almost by construction: you cannot blind a drug whose entire point is a reaction the patient has been warned about, and unsupervised patients simply stop taking it the day they decide to drink. So the tidy efficacy data look weak. But that framing misses the real finding. When disulfiram is supervised, when someone actually watches the patient take it, the effect size is roughly 0.8 versus supervised control, one of the largest signals in all of addiction medicine. The variable that makes or breaks disulfiram is not pharmacology, it's the accountability structure built around it.

A note on its origins, because it explains the whole drug: disulfiram wasn't designed as a medication. In the 1930s it was an industrial chemical used in rubber-tire manufacturing, and workers who handled it discovered they became violently ill after drinking. Someone made the connection, and by 1951 the FDA had approved it for alcoholism. Its therapeutic effect is, quite literally, a repurposed industrial accident.

Part 1: Indications: Who Is Disulfiram For?

FDA-Approved Use

• Chronic alcohol use disorder: as an adjunct in motivated patients pursuing total abstinence

That is the entire on-label story. Disulfiram is not a first-line AUD medication in most guidelines (naltrexone holds that spot), but it occupies a specific and defensible niche.

The Right Patient

Disulfiram is a precision instrument, not a broad-spectrum one. The ideal candidate has a recognizable profile:

• Committed to total abstinence, not moderation: this is non-negotiable. Disulfiram offers nothing to the patient who wants to cut back. It is for the patient who resonates with "one drink is too many, and a thousand is not enough."
• Highly motivated, typically someone who has tried and failed to control drinking despite real, sometimes catastrophic, consequences: lost jobs, lost relationships, medical damage.
• Has external support: a spouse, partner, friend, sober-living staff, or clinic that can supervise or witness the daily dose. This single feature separates disulfiram that works from disulfiram that doesn't.
• Engaged in the rest of recovery: 12-step programs, psychotherapy, or both. Disulfiram is a scaffold around behavioral change, not a substitute for it.

Where It Shines

• Severe AUD with an available supervisor. The classic win. The patient who cannot trust their own in-the-moment judgment outsources that judgment to a once-a-day decision, witnessed by someone they trust.
• Episodic, high-risk situations. Even a patient not on daily maintenance can use disulfiram tactically (starting it before a wedding, a holiday, a work event with an open bar) to take drinking off the table for a defined stretch.
• The patient who wants a commitment device. Some patients explicitly want the external constraint. Disulfiram gives it to them in a form they can see and feel.

Off-Label: Cocaine Use Disorder

Disulfiram has a secondary, dopaminergic mechanism (inhibition of dopamine β-hydroxylase) that blunts the rewarding effects of cocaine, and it has been studied, most notably in patients with combined alcohol-and-cocaine use, in roughly a thousand patients across trials. The signal is real but modest, and the doses needed appear higher: evidence suggests >350 mg/day is required for a meaningful cocaine-blunting effect, versus the standard 250 mg for alcohol. Treat this as an off-label option for the polysubstance patient, not an established indication.

Who Is a Poor Candidate

• Anyone unwilling or unable to commit to total abstinence.
• Patients with no supervision structure: unsupervised disulfiram performs no better than placebo.
• Cognitive impairment severe enough that the patient can't reliably understand and follow the "avoid all alcohol, including hidden sources" instruction (this is a safety issue, not just an efficacy one).
• Patients with the specific medical contraindications below: cardiac disease, significant hepatic impairment, active psychosis, pregnancy.

Part 2: Before You Start: Workup and Candidacy

Disulfiram has a short but genuinely important pre-start checklist. Two of these steps, confirming abstinence and screening the heart, are safety-critical.

Part 3: How to Start and Dose

Formulation

Oral tablet, 250 mg standard. That's it: no extended-release, no injectable, no liquid to fuss with. The simplicity is a feature.

Starting Dose and Titration

• Confirm 12+ hours of abstinence first (see Part 2). This is the gate.
• Start: 125–250 mg once daily. Many clinicians simply start at 250 mg.
• Timing: dose at bedtime. The main early side effect is fatigue/drowsiness, so dosing at night lets the patient sleep through it.
• Typical maintenance target: 250 mg/day. Range 125–500 mg/day. Titrate upward only if there's a specific reason.

The Dose Ceiling: Lower Is Better

The historical practice of dosing 1,000–3,000 mg/day is abandoned, and for good reason. Those high doses drove the drug's dangerous reputation: the rare deaths from disulfiram-ethanol reactions occurred largely in that high-dose era and with deliberate provocation testing. Modern low-dose disulfiram (250 mg) is both safer and just as effective as the old high doses. There is no efficacy payoff for going high in AUD.

Cocaine use disorder (off-label): the exception to "stay low." Evidence suggests >350 mg/day is needed for the cocaine-blunting effect. For AUD alone, there is no reason to climb.

There Is No Serum Level to Chase

Unlike lithium, disulfiram has no trough level, no therapeutic window to titrate into, and no steady-state blood test. Dose to a fixed milligram target and monitor adherence and liver, not a concentration. This makes the day-to-day management simpler: the entire safety system rests on abstinence confirmation, LFTs, and the supervision structure.

Set the Timeline Expectation

Tell patients what recovery feels like on a clock. The pill's protection is immediate (it's active the day they take it), but the ease comes later. Around 2–3 months of sobriety, the brain has healed enough that cravings lessen and confidence returns; paradoxically, that's often when the temptation to stop the disulfiram rises ("I feel fine now, I don't need it"). Warn patients that the good stretch is not the finish line. It's the payoff for continuing.

Part 4: Monitoring: The Schedule

Monitoring disulfiram is refreshingly light compared with lithium, but the two things you do monitor matter.

Liver Function

• Interpretation: most mildly elevated LFTs in this population reflect alcohol, not disulfiram. Mild-to-moderate elevations generally tolerate continued treatment with closer follow-up.
• Act on a clear signal: a marked or rising transaminase pattern, or clinical signs of hepatitis, warrants holding the drug and evaluating. Disulfiram-induced hepatitis is rare but can be serious.

Adherence: the Real Monitoring Target

For disulfiram, adherence is efficacy, so monitor it as deliberately as you'd monitor a lab:

• Use the supervisor. The witnessed daily dose is your primary adherence measure.
• The two-day call rule. Ask the supervisor to call you if the patient misses two consecutive doses: early warning of drift.
• Track the outcomes that matter at each visit: drinks per day, days abstinent, relapse events, and the life-domain markers that reflect real recovery (marriage/relationship stability, job retention, paying bills, stable housing). These tell you whether the whole structure is holding, not just whether the pill is being swallowed.

Cardiovascular Check-In

No routine repeat ECG is required for a stable patient, but revisit cardiac status if the patient develops new cardiac symptoms or if their risk profile changes.

Part 5: Side Effects and How to Manage Them

Disulfiram has two entirely separate side-effect stories. One is the ordinary tolerability profile of the drug taken without alcohol, mostly minor. The other is the disulfiram-ethanol reaction, which is the drug's whole reason for existing and gets its own section (Part 6). Don't conflate them.

The Everyday Side Effects (No Alcohol Involved)

These are the effects of simply taking disulfiram, and most are mild.

• Fatigue / drowsiness. Common early, usually improves. Management: dose at bedtime.
• Metallic or garlic-like taste in the mouth. Expected, harmless. Reassure.
• Bad breath / body odor. Warn the patient in advance; reinforce dental hygiene. Usually tolerable.
• Maculopapular rash. Monitor. Usually manageable, but a significant or spreading rash may require discontinuation.
• Mild nausea / GI upset. Usually mild. Be sure it isn't a low-grade reaction from an unrecognized alcohol exposure; ask about mouthwash, cough syrup, sauces.
• Headache. Generally mild.

Peripheral Neuropathy: Watch for It

Disulfiram can cause a dose- and duration-related peripheral neuropathy. Ask about and monitor for paresthesias: numbness, tingling, burning in the feet or hands. It is usually reversible if caught and the drug stopped, so take new sensory complaints seriously and examine.

Hepatotoxicity

Rare at 250 mg but real, and the reason for the LFT schedule. It can range from asymptomatic enzyme elevation to overt, occasionally severe, hepatitis. Counsel the patient to report jaundice, dark urine, right-upper-quadrant pain, unusual fatigue, or loss of appetite immediately. Baseline and periodic LFTs plus symptom vigilance are the safety net (Part 4).

Psychiatric Effects

• Psychosis: disulfiram can worsen or precipitate psychosis via its dopaminergic effects, hence the contraindication in psychotic patients. If new psychotic symptoms emerge, stop the drug.
• Depression / mood changes: exercise caution in severe depression with suicidal ideation; the mechanism of any mood effect is unclear, but the caution is warranted.

Part 6: The Disulfiram-Ethanol Reaction: Toxicity and Its Mechanism

This is disulfiram. Understanding it cold, and teaching it to your patient cold, is the core of prescribing this drug safely.

The Mechanism

Normally, the body metabolizes alcohol in two steps: alcohol to acetaldehyde (via alcohol dehydrogenase), then acetaldehyde to harmless acetate (via aldehyde dehydrogenase). Disulfiram irreversibly inhibits aldehyde dehydrogenase. The second step stalls. Acetaldehyde, the toxic intermediate responsible for much of a hangover's misery, accumulates to high levels the moment alcohol enters the system. The reaction is essentially an instant, amplified, chemically enforced hangover.

Because the enzyme inhibition is irreversible, the effect does not switch off when the last pill wears off. The body has to synthesize new enzyme. This is why the disulfiram-ethanol reaction can persist for up to two weeks after the last dose, a fact with real clinical value: a patient who impulsively decides to drink two days after quitting the drug is still protected, which builds in a window for reconsideration.

The Reaction, in Order

• Onset: 5–15 minutes after alcohol ingestion.
• Typical symptoms: flushing (face, neck), throbbing headache, a pounding sensation in the head and neck, sweating, thirst, nausea and often copious vomiting, chest pain, palpitations, tachycardia, shortness of breath and hyperventilation, hypotension, dizziness/vertigo, blurred vision, weakness, marked uneasiness, and confusion.
• Severe reactions (uncommon): respiratory depression, cardiovascular collapse, arrhythmias, myocardial infarction, acute heart failure, seizures, unconsciousness, and, historically and rarely, death.

How Dangerous Is It, Really?

Honest framing matters here, because the drug's reputation outruns the modern data. Deaths from the disulfiram-ethanol reaction have not been reported in many years with standard 250 mg dosing. The historical fatalities clustered in the era of 1,000–3,000 mg dosing and deliberate provocation ("challenge") testing, which is no longer done. Lowering the dose to 250 mg is what tamed the safety profile. That is precisely why you screen out cardiac and cerebrovascular patients up front: the danger is concentrated in the patient whose heart or vessels can't absorb the stress, not in the reaction per se at modern doses.

Management of a Reaction

• Most reactions are self-limited and supportive care (rest, reassurance, fluids, antiemetics) suffices.
• A severe reaction is an emergency: significant chest pain, syncope, hypotension, arrhythmia, respiratory distress warrants ED evaluation and supportive/resuscitative care. There is no specific antidote; treatment is supportive (IV fluids for hypotension, oxygen, cardiac monitoring).

Hidden Alcohol: the Education That Prevents Accidental Reactions

Most disulfiram reactions in practice are accidental: the patient never meant to drink. The job at prescribing is to inventory the hidden sources with the patient, explicitly:

Part 7: Drug Interactions

Disulfiram's interactions come from two directions: it inhibits several hepatic metabolizing enzymes (raising levels of other drugs), and one antibiotic must be actively avoided.

Disulfiram Raises Levels of These Drugs (via Enzyme Inhibition)

Disulfiram inhibits hepatic metabolism (including CYP2C9, CYP2D6, and related pathways), so co-administered drugs cleared by those routes can accumulate:

• Warfarin: reduced clearance can raise the INR and bleeding risk. Monitor INR closely and adjust the warfarin dose when starting or stopping disulfiram.
• Phenytoin: levels can rise into the toxic range. Monitor phenytoin levels and watch for toxicity.
• Benzodiazepines metabolized by oxidation, especially chlordiazepoxide and diazepam: reduced clearance, increased sedation and accumulation. Prefer benzodiazepines cleared by glucuronidation (lorazepam, oxazepam, temazepam), which are largely spared, if a benzodiazepine is needed. Monitor either way.
• Tricyclic antidepressants: reduced clearance; monitor for elevated TCA effects/levels.
• Other anticonvulsants (e.g., valproate): levels can shift; monitor.

The combination has been associated with confusional states and psychotic reactions, and both drugs independently produce disulfiram-like reactions with alcohol. Avoid the pairing. Be alert that metronidazole itself, and other agents like certain cephalosporins, can independently cause a disulfiram-like reaction with alcohol even in patients not on disulfiram.

Alcohol: the Intended "Interaction"

The disulfiram-ethanol reaction (Part 6) is, mechanistically, a drug interaction, the one deliberately being set up. Everything in the hidden-alcohol education section is interaction management.

Management Strategy

• Before starting disulfiram, review the full medication list for warfarin, phenytoin, oxidatively metabolized benzodiazepines, TCAs, and anticonvulsants, and plan to monitor levels/effects.
• Time INR and phenytoin checks around both starting and stopping disulfiram; the enzyme inhibition unwinds gradually given the drug's long duration of action.
• Screen specifically for metronidazole (including short courses for dental or GI infections) and avoid.

Part 8: Special Populations

Pregnancy

Contraindicated. Disulfiram is considered teratogenic, and the disulfiram-ethanol reaction poses added risk. For AUD in pregnancy, favor non-pharmacologic support and safer strategies; do not use disulfiram.

Lactation

Avoid. Disulfiram is expected to pass into breast milk, and safety data are lacking.

Hepatic Impairment

A relative-to-absolute contraindication depending on severity. Disulfiram is hepatotoxic and requires at least fair liver function. Cirrhosis or significant hepatic impairment is a contraindication. Mild-to-moderate transaminase elevation (common from alcohol itself) does not automatically bar treatment, but demands baseline LFTs, closer monitoring, and a low threshold to stop.

Cardiac and Cerebrovascular Disease

Contraindicated in significant cardiovascular or cerebrovascular disease. The disulfiram-ethanol reaction is a physiologic stress test; a heart or cerebral circulation that can't tolerate tachycardia and hypotension turns a manageable reaction into a catastrophe. This is the screening step you cannot skip (Part 2). Heart failure is at minimum a strong relative contraindication.

Elderly

No fixed dose adjustment, but two age-linked concerns dominate: cardiovascular disease is more prevalent (making the cardiac screen more important), and cognitive changes may threaten both comprehension of the abstinence instruction and reliable adherence. Assess both carefully before prescribing.

Renal Impairment

Disulfiram is hepatically metabolized, and no specific renal dose adjustment is standard. Renal impairment is not a primary concern for this drug the way hepatic and cardiac status are.

Cognitive Impairment

A contraindication when significant. The patient must understand the mechanism, commit to abstinence, and reliably avoid hidden alcohol sources, all of which require intact cognition. This is a safety line, not just an efficacy one.

Active Psychosis

Contraindicated. Disulfiram's dopaminergic activity can worsen or precipitate psychosis.

Part 9: Discontinuation

Stopping disulfiram is mechanically simple, and this is one of the few places it's easier than the alternatives.

• No withdrawal syndrome, no taper required. Disulfiram can be discontinued abruptly. There is nothing analogous to lithium's rebound or baclofen's seizure risk.
• But the drug's effect lingers. Because aldehyde dehydrogenase inhibition is irreversible, the alcohol reaction persists for up to two weeks after the last dose. Patients must understand this: quitting the pill does not make it safe to drink that evening. This lingering window is a safety feature, it protects the impulsive patient in the days after they stop, but it must be taught, not assumed.
• The relapse vulnerability outlives the drug. Disulfiram was never treating the craving; it was containing it. When the pill stops, the underlying AUD is still there. Discontinuation should be a planned step within an intact recovery structure, ongoing therapy, support groups, and other AUD pharmacotherapy if appropriate, not a solo decision made during a good stretch. The dangerous moment is precisely the 2–3-month mark when the patient feels well and reasons themselves off the drug.

Part 10: Disulfiram vs the Alternatives

Choosing among AUD medications is mostly about matching mechanism to patient goal. Disulfiram sits at one pole (deterrence) while the others cluster around craving and reward.

The Mechanistic Map

vs Naltrexone

Naltrexone is first-line for AUD and has the strongest evidence base (it was the winner in the large COMBINE trial). It works by blunting the euphoric rush after the first drink, so it reduces heavy drinking and supports harm reduction: it does not require the patient to commit to total abstinence, and it needs no supervisor. It's also gentler on the cardiovascular system. Choose naltrexone as the default; reach for disulfiram when the patient specifically wants (or needs) a hard external constraint, is committed to abstinence, and has a supervision structure, or when opioid use precludes naltrexone. Naltrexone dosing: 50 mg PO daily, or 380 mg IM monthly (Vivitrol).

vs Acamprosate

Acamprosate works via GABA-glutamate rebalancing and is the safest of the three (no cardiac risk, no hepatotoxicity, usable in liver disease) but it is also the weakest, and it flatly failed to beat placebo in COMBINE. Its high TID pill burden hurts adherence. In multiple head-to-head comparisons, supervised disulfiram outperforms acamprosate. Acamprosate's niche is the post-detox patient who needs a safe maintenance agent, especially with hepatic disease that rules disulfiram out.

vs Topiramate

Topiramate (off-label) reduces heavy-drinking days by roughly 23% via GABA-up/glutamate-down mechanisms and, like naltrexone, permits moderation rather than demanding abstinence. Its cognitive and sensory side effects ("Dopamax": word-finding trouble, paresthesias) are the trade-off. A different tool for a different patient, one who wants to cut down rather than commit to a deterrent.

An Honest Word on the Efficacy Comparison

Disulfiram's headline effect sizes (roughly 0.8 supervised) are partly inflated by an apples-to-oranges artifact: disulfiram is scored against a total-abstinence standard, while naltrexone and topiramate "succeed" by reducing drinking without full abstinence. So don't read a bigger number as unambiguous superiority. The truthful summary: supervised disulfiram is genuinely effective in the right, committed patient; unsupervised disulfiram is not; and naltrexone remains the more broadly useful first-line agent.

Why Disulfiram Fell Out of Use, and Why That's Partly a Mistake

Disulfiram declined for reasons that are mostly not clinical: it fails conventional double-blind RCTs (you can't blind the reaction), unsupervised use looks like placebo, and its 1,000–3,000 mg-era reputation for danger stuck long after low-dose practice made it safe. But recent meta-analyses and the alcohol-mortality crisis have revived interest: in pooled analyses, disulfiram carries a larger effect size than other AUD medications, and modern editors no longer regard it as a "deadly poison." For the committed, supervised patient, it is one of the more powerful things you can offer.

Mechanism: The Short Version

Disulfiram's primary action is irreversible inhibition of aldehyde dehydrogenase. Blocking this enzyme stalls alcohol metabolism at acetaldehyde, which accumulates and produces the aversive disulfiram-ethanol reaction. Because inhibition is irreversible, the effect persists until new enzyme is synthesized, hence the roughly two-week duration after stopping, consistent with the drug's long biological action (elimination half-life on the order of days, with an active metabolite, diethyldithiocarbamate). A secondary mechanism (inhibition of dopamine β-hydroxylase, raising CNS dopamine) underlies its blunting of cocaine reward and also its capacity to worsen psychosis. Critically, the therapeutic effect in AUD is not pharmacologic craving-reduction at all: it is behavioral and psychological, a daily, witnessed act that installs a healthy fear of drinking. The pharmacology is the deterrent's enforcement mechanism; the accountability structure is the treatment.

Bedside Cheat Sheet